Publication
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Thyroid Gland Neoplasmcivic_curation1.00
- cancerThyroid Gland Medullary Carcinomacivic_curation1.00
- drugSelpercatinibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET Fusioncivic_curation1.00
- variantRET Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32846061
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET Fusion1 | ||||||||
| Selpercatinib | Malignant Thyroid Gland Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8852In this phase 1/2 trial (NCT03157128), patients with RET altered thyroid cancers were enrolled to receive the highly selective RET inhibitor selpercatinib. Among 19 patients with previously treated RE… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC | civic |
| RET Mutation + RET Fusion1 | ||||||||
| Selpercatinib | Malignant Thyroid Gland Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11268In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC | civic |
| RET Mutation1 | ||||||||
| Selpercatinib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8851In this international phase 1/2 trial (NCT03157128), 55 RET-mutant medullary thyroid cancer patients who had previously received the multi-kinase inhibitors vandetanib and/or cabozantinib received th… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC | civic |